At 11.9% CAGR, North America Traumatic Brain Injury Diagnostics Equipment Market Projected to be Worth US$ 3,340.17 Million by 2030, says Business Market Insights

According to Business Market Insights’ research, the North America traumatic brain injury diagnostics equipment market was valued at US$ 1,360.02 million in 2022 and is expected to reach US$ 3,340.17 million by 2030, registering a CAGR of 11.9% from 2022 to 2030. Emergence of portable non-invasive monitoring devices to diagnose TBI patients and growing use of MRI over CT to limit inpatient mortality and marginally reduce diagnostic cost are among the critical factors attributed to drive the North America traumatic brain injury diagnostics equipment market growth.

New noninvasive methods for monitoring tissue metabolism can help improve the diagnosis and monitoring of brain conditions such as concussions, stroke, and TBI, owing to which patients can recover more quickly. The consequences of TBI resulted in increasing healthcare burden costs, accounting for US$ 76.5 billion annually, as per the BrainScope company white paper. The installation of "BrainScope One" in less expensive care settings—e.g., emergency department and community settings (including urgent care centers)—may result in a significant reduction of healthcare costs by up to 32.2%, as per the findings revealed in the white paper. BrainScope One aids in eliminating unnecessary CT scans, thereby reducing healthcare costs for TBI.

On the contrary, adverse effects of contrast medium/agent hamper the growth of North America traumatic brain injury diagnostics equipment market.

Based on techniques, the North America traumatic brain injury diagnostics equipment market is segmented into non-invasive, invasive, and combination techniques. The invasive segment held 59.5% market share in 2022, amassing US$ 809.48 million. It is projected to garner US$ 1,931.93 million by 2030 to register 11.5% CAGR during 2022–2030. Furthermore, the non-invasive segment is subcategorized into electroencephalography (EEG), brain–computer interface (BCI), eye tracking and near-infrared spectroscopy (NIRS), magnetic resonance imaging (MRI), magnetoencephalography (MEG), transcranial magnetic stimulation (TMS), cerebral metabolic rate of oxygen (CMRO2), intracranial pressure, and others .Additionally, invasive segment is subsegmented into cerebral perfusion pressure (CPP) and pressure reactivity index (PRx), partial brain tissue oxygen pressure (PbtO2), cerebral microdialysis (CMD), intracranial pressure, and others.

In terms of device, the North America traumatic brain injury diagnostics equipment market is bifurcated into imaging devices and monitoring devices. The imaging devices segment held 79.4% share of North America traumatic brain injury diagnostics equipment market in 2022, amassing US$ 1,080.08 million. It is anticipated to garner US$ 2,585.81 million by 2030 to expand at 11.5% CAGR during 2022–2030.

By end user, the North America traumatic brain injury diagnostics equipment market is divided into hospitals and clinics, diagnostic centers, and others. The hospitals and clinics segment held 50.1% share of North America traumatic brain injury diagnostics equipment market in 2022, amassing US$ 681.01 million. It is projected to garner US$ 1,667.19 million by 2030 to expand at 11.8% CAGR from 2022 to 2030.

Based on country, the North America traumatic brain injury diagnostics equipment market is categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 86.0% share of North America traumatic brain injury diagnostics equipment market in 2022. It was assessed at US$ 1,170.03 million in 2022 and is likely to hit US$ 2,849.50 million by 2030, registering a CAGR of 11.8% during 2022–2030.

Key players operating in the North America traumatic brain injury diagnostics equipment market are GE HealthCare Technologies Inc, Elekta AB, Integra LifeSciences Holdings Corp, Natus Medical Inc, Raumedic AG, BrainScope Co Inc, Soterix Medical Inc, Medtronic Plc, Vivonics Inc, NanoDx Inc, Compumedics Ltd, Sense Diagnostics Inc, NeuraSignal Inc, Neurovigil Inc., and Luciole Medical AG, among others.

• In April 2022, NeuraSignal Inc announced the upgradation of its NovaSignal Platform. A new feature called Morphology has been added to the platform, providing advanced analysis of cerebral waveforms. The new feature enabled faster and easier assessment of patients with suspected neurological conditions such as stroke.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com